Mapi Pharma Group (Mapi) is an international pharmaceutical company specializing in complex bulk Active Pharmaceutical Ingredients (APIs), generic and innovative intermediates, high development barrier generics and novel finished dosage forms based on selected drug delivery systems.
Mapi is built on strong chemical and pharmaceutical R&D capabilities, deep understanding of the global market and regulatory needs and its ability to employ local cooperation and enduring relationships in all the countries it is present in. Mapi, headquartered in Israel with its R&D facilities in Israel, China and Germany, was able to secure its IP position by over 20 patents applications for APIs and formulations in less than two years of operation.
Mapi’s lead product candidate is Glatiramer Acetate Depot, a once-monthly injection for the treatment of patients with relapsing-remitting multiple sclerosis, or RRMS, in contrast to the daily 20 mg and the three-weekly 40 mg dosage of Copaxone, Teva. Branded copaxone had sales of $4.2 billion in 2015 (according to Thomson Retuers.
Mapi’s investors include: Crossroad, Jingxin Pharmaceutical and Shavit Capital.
www.mapi-pharma.com
Mapi is built on strong chemical and pharmaceutical R&D capabilities, deep understanding of the global market and regulatory needs and its ability to employ local cooperation and enduring relationships in all the countries it is present in. Mapi, headquartered in Israel with its R&D facilities in Israel, China and Germany, was able to secure its IP position by over 20 patents applications for APIs and formulations in less than two years of operation.
Mapi’s lead product candidate is Glatiramer Acetate Depot, a once-monthly injection for the treatment of patients with relapsing-remitting multiple sclerosis, or RRMS, in contrast to the daily 20 mg and the three-weekly 40 mg dosage of Copaxone, Teva. Branded copaxone had sales of $4.2 billion in 2015 (according to Thomson Retuers.
Mapi’s investors include: Crossroad, Jingxin Pharmaceutical and Shavit Capital.
www.mapi-pharma.com
Location: Israel, Center District, Nes Ziona
Employees: 11-50
Total raised: $20M
Founded date: 2008
Investors 2
| Date | Name | Website |
| - | Crossroad | crossroad-... |
| - | Shavit Cap... | shavitcapi... |
Funding Rounds 2
| Date | Series | Amount | Investors |
| 18.08.2017 | - | $10M | - |
| 27.05.2015 | Series A | $10M | - |
Mentions in press and media 5
| Date | Title | Description |
| 18.08.2017 | Mapi Pharma Receives $10m in Funding | Mapi Pharma Ltd., Ness Ziona, Israel-based clinical stage biopharmaceutical company, received $10m in funding. aMoon Fund, an Israeli vc firm focused on innovative healthcare and life science ventures, founded by Marius Nacht and Dr. Yair S... |
| 17.08.2017 | Mapi Pharma Ltd. Announces Closing of $10 Million Investment | - |
| 26.01.2016 | Mapi Pharma swings for $50M haul as oft-delayed IPO nears D-Day | Mapi Pharma has set the terms for its latest crack at listing on Nasdaq. The biotech, which set terms on its first IPO attempt back in April 2014, is aiming to round up around $50 million (€46 million) to bankroll development of its once-a-... |
| 28.05.2015 | Mapi Pharma closes $10M Series A round after two scuttled IPOs | Mapi Pharma has closed a $10 million (€9 million) Series A round to finance mid-phase trials of its once-a-month version of Teva's ($TEVA) blockbuster multiple sclerosis drug, Copaxone. The round follows two aborted attempts to raise cash i... |
| 27.05.2015 | Mapi Pharma Receives $10M in Series A Financing | Mapi Pharma Ltd., a Ness Ziona, Israel-based development stage pharmaceutical company, received $10m in Series A financing. The round was led by Shavit Capital with participation from chairman and CEO Mr. Ehud Marom. The company intends to ... |